Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,819 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neoplasm of Lung Clear all
Terminated Phase 1Phase 2 Interventional Results available

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma

NCT02408016
View directory record Official record
Conditions
Advanced Pleural Malignant Mesothelioma, HLA-A*0201 Positive Cells Present, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Pleural Malignant Mesothelioma, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage III Pleural Malignant Mesothelioma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IV Pleural Malignant Mesothelioma AJCC v7, WT1 Positive
Interventions
Aldesleukin, Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes, Cyclophosphamide, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
Biological · Drug · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 27, 2026, 1:41 PM EDT
Completed Phase 1 Interventional

Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer

NCT01545947
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
Interventions
CC-223, erlotinib, CC-223, oral azacitidine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 27, 2026, 1:41 PM EDT
Active, not recruiting Phase 3 Interventional

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

NCT05120349
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Osimertinib, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
15
States / cities
Anchorage, Alaska • Los Angeles, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 27, 2026, 1:41 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

NCT02912949
View directory record Official record
Conditions
Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
Interventions
zenocutuzumab (MCLA-128)
Drug
Lead sponsor
Partner Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
26
States / cities
Phoenix, Arizona • Cerritos, California • Irvine, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 27, 2026, 1:41 PM EDT
Withdrawn Not applicable Interventional

Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer

NCT02059889
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
diffusion-weighted magnetic resonance imaging, 4-dimensional computed tomography, fludeoxyglucose F 18, FDG-PET
Device · Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 27, 2026, 1:41 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

NCT05797168
View directory record Official record
Conditions
Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
Interventions
Torvutatug samrotecan, Saruparib, Bevacizumab, Carboplatin, Palacaparib, Pembrolizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
13
States / cities
Duarte, California • Irvine, California • La Jolla, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 27, 2026, 1:41 PM EDT
Active, not recruiting Phase 2 Interventional

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

NCT06773910
View directory record Official record
Conditions
Limited Stage Small Cell Lung Cancer
Interventions
BMS-986489, Durvalumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
34
States / cities
Daphne, Alabama • Santa Barbara, California • Fort Myers, Florida + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 27, 2026, 1:41 PM EDT
Terminated Not applicable Interventional Results available

Treatment Resistance Following Anti-cancer Therapies

NCT04436120
View directory record Official record
Conditions
Disease Progression
Interventions
De novo tumor tissue biopsy, Research blood draws
Procedure
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
17
States / cities
Daphne, Alabama • Mobile, Alabama • Anchorage, Alaska + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Oct 27, 2026, 1:41 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT03178552
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Alectinib, Atezolizumab, Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Entrectinib, Cobimetinib, Vemurafenib, Bevacizumab, Divarasib, Docetaxel
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
12
States / cities
Sacramento, California • Denver, Colorado • Fort Myers, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 27, 2026, 1:41 PM EDT
Completed Phase 1Phase 2 Interventional

A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens

NCT03953235
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Shared Neoantigen-Positive Solid Tumors
Interventions
GRT-C903, GRT-R904, nivolumab, ipilimumab
Biological
Lead sponsor
Gritstone bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
12
States / cities
Phoenix, Arizona • Santa Monica, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 27, 2026, 1:41 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer

NCT04619797
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Tiragolumab, Atezolizumab, Pemetrexed, Carboplatin, Cisplatin, Tiragolumab Matching Placebo, Pembrolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
11
States / cities
Los Angeles, California • Whittier, California • Fort Myers, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 27, 2026, 1:41 PM EDT
Recruiting Phase 1Phase 2 Interventional

Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

NCT07064018
View directory record Official record
Conditions
Soft-tissue Sarcoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Ovarian Cancer, KRAS Mutation-Related Tumors
Interventions
Spedox-6, Pegfilgrastim, Filgrastim
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 27, 2026, 1:41 PM EDT
Completed Phase 1 Interventional

Gene Therapy in Treating Patients With Cancer

NCT00004178
View directory record Official record
Conditions
Cancer
Interventions
therapeutic autologous lymphocytes
Biological
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2011 · Synced Oct 27, 2026, 1:41 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer

NCT07328490
View directory record Official record
Conditions
Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Small Cell Carcinoma
Interventions
Tarlatamab, Sacituzumab Govitecan
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 27, 2026, 1:41 PM EDT
Completed Phase 2 Interventional

Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer

NCT00021333
View directory record Official record
Conditions
Head and Neck Cancer, Lung Cancer
Interventions
filgrastim, cisplatin, paclitaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
18
States / cities
Flemington, New Jersey • Lakewood, New Jersey • Millville, New Jersey + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 27, 2026, 1:41 PM EDT
Completed No phase listed Observational

Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Non-Small Cell Lung Cancer And Bronchial Disease

NCT00754910
View directory record Official record
Conditions
Lung Cancer
Interventions
porfimer sodium, bronchoscopy
Drug · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 27, 2026, 1:41 PM EDT
Completed Phase 1 Interventional

Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer

NCT02194049
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
BKM120, cisplatin, etoposide
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 27, 2026, 1:41 PM EDT
Completed Not applicable Interventional Results available

Improving Goals of Care Discussion in Advanced Cancer Patients

NCT02374255
View directory record Official record
Conditions
Primary Stage IV Hepatobiliary, Esophageal, Colorectal Cancer, Glioblastoma, Cancer of Stomach, Cancer of Pancreas, Melanoma, Head or Neck Cancer, Stage III, Stage IV, Lung Cancers, Pancreatic Cancers
Interventions
GoC intervention
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
New Haven, Connecticut • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 27, 2026, 1:41 PM EDT
Completed Phase 2 Interventional Results available

Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer

NCT02581943
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pembrolizumab, Quality-of-Life Assessment
Drug · Other · Biological
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 27, 2026, 1:41 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

NCT04161391
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET Gene Mutation, Metastatic Solid Tumor, Advanced Solid Tumor
Interventions
TPX-0046
Drug
Lead sponsor
Turning Point Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
20
States / cities
La Jolla, California • Orange, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 27, 2026, 1:41 PM EDT
Active, not recruiting Phase 1 Interventional

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

NCT04886804
View directory record Official record
Conditions
Neoplasm Metastasis, Non-Small Cell Lung Cancer
Interventions
zongertinib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
20
States / cities
Birmingham, Alabama • Beverly Hills, California • Duarte, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 27, 2026, 1:41 PM EDT
Completed Phase 1 Interventional

Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer

NCT00850785
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
DRibble vaccine
Biological
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 27, 2026, 1:41 PM EDT
Terminated Phase 2 Interventional Results available

Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer

NCT00129974
View directory record Official record
Conditions
Carcinoma, Small Cell
Interventions
pemetrexed and gemcitabine
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
Boston, Massachusetts • Quincy, Massachusetts • Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 16, 2017 · Synced Oct 27, 2026, 1:41 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors

NCT04875806
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Ovarian Cancer, Non-small Cell Lung Cancer, Breast Cancer
Interventions
NC762
Drug
Lead sponsor
NextCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
New Haven, Connecticut • Chicago, Illinois • Hackensack, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 27, 2026, 1:41 PM EDT